Advertisement

Effects of 24 Weeks of Lansoprazole Therapy on Asthma Symptoms, Exacerbations, Quality of Life, and Pulmonary Function in Adult Asthmatic Patients With Acid Reflux Symptoms

      Background

      Difficult-to-control asthma has been associated with gastroesophageal acid reflux. Acid-suppressive treatment has been inconsistent in improving asthma control.

      Objective

      To determine whether a proton-pump inhibitor improves asthma control in adult asthmatic patients with acid reflux symptoms.

      Design

      Multicenter, double-blind, randomized, placebo-controlled trial.

      Setting

      Twenty-nine private practices and 3 academic practices in the United States.

      Patients

      Two hundred seven patients receiving usual asthma care including an inhaled corticosteroid (ICS). Patients had acid reflux symptoms and moderate-to-severe persistent asthma.

      Intervention

      Lansoprazole, 30 mg bid, or placebo, bid, for 24 weeks.

      Measurements

      The primary outcome measure was daily asthma symptoms by diary. Secondary asthma outcomes included rescue albuterol use, daily morning and evening peak expiratory flow, FEV1, FVC, asthma quality of life with standardized activities (AQLQS) questionnaire score, investigator-assessed symptoms, exacerbations, and oral corticosteroid-treated exacerbations.

      Results

      Daily asthma symptoms, albuterol use, peak expiratory flow, FEV1, FVC, and investigator-assessed asthma symptoms at 24 weeks did not improve significantly with lansoprazole treatment compared to placebo. The AQLQS emotional function domain improved at 24 weeks (p = 0.025) with lansoprazole therapy. Fewer patients receiving lansoprazole (8.1% vs 20.4%, respectively; p = 0.017) had exacerbations and oral corticosteroid-treated (ie, moderate-to-severe) exacerbations (4% vs 13.9%, respectively; p = 0.016) of asthma. A post hoc subgroup analysis revealed that fewer patients receiving one or more long-term asthma-control medications in addition to an ICS experienced exacerbations (6.5% vs 24.6%, respectively; p = 0.016) and moderate-to-severe exacerbations (2.2% vs 17.5%, respectively; p = 0.021) with lansoprazole therapy.

      Conclusion

      In adult patients with moderate-to-severe persistent asthma and symptoms of acid reflux, treatment with 30 mg of lansoprazole bid for 24 weeks did not improve asthma symptoms or pulmonary function, or reduce albuterol use. However, this dose significantly reduced asthma exacerbations and improved asthma quality of life, particularly in those patients receiving more than one asthma-control medication.

      Key words

      Abbrevationss:

      AQLQS (asthma quality-of-life questionnaire with standardized activities), CI (confidence interval), ICS (inhaled corticosteroid), ICS+ (inhaled corticosteroid plus at least one other long-term asthma-control medication), PPI (proton-pump inhibitor)
      To read this article in full you will need to make a payment
      Subscribe to CHEST
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Gibson PG, Henry RL, Coughlan JL. Gastro-esophageal reflux treatment for asthma in adults and children. Cochrane Database Syst Rev (database online). Issue 2, 2002

        • Sontag SJ
        • O’Connell S
        • Khandelwal S
        • et al.
        Asthmatics with gastroesophageal reflux: long term results of a randomized trial of medical and surgical antireflux therapies.
        Am J Gastroenterol. 2003; 98: 987-999
        • Juniper EF
        • Buist S
        • Cox FM
        • et al.
        Validation of a standardized version of the asthma quality of life questionnaire.
        Chest. 1999; 115: 1265-1270
        • De Vault KR
        • Castell DO
        Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease: the Practice Parameters Committee of the American College of Gastroenterology.
        Am J Gastroenterol. 1999; 94: 1434-1442
      2. National Asthma Education and Prevention Program.
        Expert panel report II: guidelines for the diagnosis and management of asthma. 1997; (April National Heart, Lung, and Blood Institute. Bethesda, MD: NIH Publication No. 97–4051)
        • Crapo RO
        • Morris AH
        • Gardner RM
        Reference spirometric values using techniques and equipment that meet ATS recommendations.
        Am Rev Respir Dis. 1981; 123: 659-664
        • Ayres JG
        • Campbell LM
        A controlled assessment of an asthma self-management plan involving a budesonide dose regimen: OPTIONS Research Group.
        Eur Respir J. 1996; 9: 886-892
        • Robinson DS
        • Campbell D
        • Barnes PJ
        Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial.
        Lancet. 2001; 357: 2007-2011
        • Pauwels RA
        • Lofdahl CG
        • Postma DS
        • et al.
        Effect of inhaled formoterol and budesonide on exacerbations of asthma: Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group.
        N Engl J Med. 1997; 337: 1405-1411
        • Harding SM
        • Richter JE
        • Guzzo MR
        • et al.
        Asthma and gastroesophageal reflux: acid suppressive therapy improves asthma outcome.
        Am J Med. 1996; 100: 395-405
        • Ringal N
        • Cuchalin A
        • Chovan L
        • et al.
        Evaluation of different inhaled combination therapies (EDICT): a randomised, double-blind comparison of SeretideTM (50/250 μg bd Diskus vs. formoterol (12 μg bd) and budesonide (800 μg bd) given concurrently (both via Turbuhaler) in patients with moderate-to-severe asthma.
        Respir Med. 2002; 96: 851-861
        • Soler M
        • Matz J
        • Townley R
        • et al.
        The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.
        Eur Respir J. 2001; 18: 254-261
      3. National Institutes of Health. Global initiative for asthma. 2002 National Institutes of Health. Bethesda, MD: NIH Publication No 02–3659

        • Shrewsbury
        • Pyke S
        • Britton M
        Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA).
        BMJ. 2000; 320: 1368-1373
        • Pauwels RA
        Similarities and differences in asthma and chronic obstructive pulmonary disease exacerbations.
        Proc Am Thorac Soc. 2004; 1: 73-79
        • Juniper EF
        • Guyatt GH
        • Willan A
        • et al.
        Determining a minimal important change in a disease-specific quality of life questionnaire.
        J Clin Epidemiol. 1994; 47: 81-87
        • Levin TR
        • Sperling RM
        • Mc Quaid KR
        Omeprazole improves peak expiratory flow rate and quality of life in asthmatics with gastroesophageal reflux.
        Am J Gastroenterol. 1998; 93: 1060-1063
        • Harding SM
        • Guzzo MR
        • Richter JE
        24-hour pH testing in asthmatics: Respiratory symptom correlation with esophageal acid events.
        Chest. 1999; 115: 654-659
        • Kiljander TO
        • Salomaa E-RM
        • Hietanen EK
        • et al.
        Gastroesophageal reflux in asthmatics: a double-blind, placebo-controlled crossover study with omeprazole.
        Chest. 1999; 116: 1257-1264
        • O’Connor JFB
        • Singer ME
        • Richter JE
        The cost-effectiveness of strategies to assess gastroesophageal reflux as an exacerbating factor in asthma.
        Am J Gastroenterol. 1999; 94: 1472-1480
        • Larrain A
        • Carrasco E
        • Galleguillos F
        • et al.
        Medical and surgical treatment of nonallergic asthma associated with gastroesophageal reflux.
        Chest. 1991; 99: 1330-1335
        • Frazzoni M
        • De Micheli E
        • Grisendi A
        • et al.
        Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole.
        Aliment Pharmacol Ther. 2003; 17: 235-241
        • Timmer W
        • Ripke H
        • Kleist P
        • et al.
        Effect of four lansoprazole dose levels and one dosage regimen of omeprazole on 24-hour intragastric pH in healthy patients.
        Methods Find Exp Clin Pharmacol. 1995; 17: 489-495